A Phase 4 interventional study of Ferric Derisomaltose and Saline (NaCl 0,9 %) (placebo) in Hip Fracture and Anemia, sponsored by Soren Overgaard. Recruiting at 3 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Soren Overgaard · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Hip Fractures with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Denmark.
Among the 57 studies in Hip Fractures with a site in Denmark, this one is the 14th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 in phase 4, and was the 53rd registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →8 of the 57 studies in Hip Fractures with a site in Denmark are open now. Recruiting first, the newest first:
Peter Gaarsdal Uhrbrand · Sites in Denmark
Ages 65+
Odense University Hospital · Sites in Denmark
Ages 18–65
University of Aarhus · Sites in Denmark
Ages 75+
University Hospital Bispebjerg and Frederiksberg · Sites in Denmark
Ages 18+
Lolland Community, Denmark · Sites in Denmark
Ages 65+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 90 across the 45 interventional studies, 230 across the 12 observational. Of the 39 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 57 have an industry lead sponsor. The 10 most frequent:
Soren Overgaard is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Soren Overgaard has 2 studies filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
4 of the studies in Hip Fractures with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06938789University of AarhusHow Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study | 2026-12-31 |
| NCT07867899Peter Gaarsdal UhrbrandDexmedetomidine for Prevention of Delirium After Hip Fracture Surgery | 2027-03-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
| NCT06898814Soren OvergaardThe Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 57 studies in Hip Fractures with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture
The main questions it aims to answer are:
It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration.
The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score.
Participants will:
- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery.
This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ferric Derisomaltose
Drug: Saline (NaCl 0,9 %) (placebo)
The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%
Single dose of 100 mL isotonic sodium chloride 0.9%
New Mobility Score (NMS)
The primary outcome is to compare the effect of a single dose of FDI (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility measured with New Mobility Score. New Mobility Score is a validated patient reported outcome measurement 0-9-point score for hip fracture patients, with 9 point equal to a fully independent indoor, outdoor and during shopping walking ability and 0 point, indicating no walking ability. Higher scores indicate a better outcome.
Time frame: Measured as the change from baseline (reported as pre-fracture NMS) in the New Mobility Score after 4, 6 and 12 weeks
Hemoglobin
Time frame: Measured at baseline, 6 and 12 weeks after intervention.
Red blood cell transfusion requirement
This will be measured by the proportion of patients who receive at least one red blood cell unit and the amounts of units per patient
Time frame: Measured on postoperative day (POD) 7 and POD 30
Fatigue, assessed using the Verbal Rating Scale for Fatigue (F-VRS)
Fatigue will be assessed using the Verbal Rating Scale for Fatigue (F-VRS). This scale, ranging from 0 to 4, measures fatigue in hip fracture patients, where 0 indicates no fatigue and 4 represents extreme fatigue.
Time frame: Measured at baseline, 4, 6 and 12 weeks after intervention.
Quality of life with EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L )
The EQ-5D-5L questionnaire measures health-related quality of life across five dimensions, with scores ranging from 1 (no problems) to 5 (extreme problems). Higher scores indicate worse outcomes, reflecting greater health issues.
Time frame: Measured as a retrograde baseline the weeks prior to admission and at 6 and 12 weeks after intervention
EuroQol Visual Analogue Scale (EQ VAS 0-100)
The EQ VAS 0-100 (range) is a visual analogue scale where 0 represents the worst imaginable health state and 100 represents the best. Higher scores on the EQ VAS indicate a better health outcome.
Time frame: Measured as a retrograde baseline the weeks prior to admission and at 6 and 12 weeks after intervention
Fear of falls measured with, Short Falls Efficacy Scale International (Short-FES-I)
Short Falls Efficacy Scale International (Short-FES-I) measures concern about falling during various activities, with scores ranging from 7 (no concern about falling) to 28 (severe concern about falling). Higher scores indicate greater concern about falling.
Time frame: Measured at baseline and at 6 and 12 weeks after intervention.
30 second Sit-to-Stand-Test (STS)
Participants are encouraged to stand and fully sit as many times as possible within 30 seconds, with correct form monitored by the tester. If a participant uses their arms, they score a 0, and only correctly executed stands are counted. This test assesses a wide range of ability levels. Lower score indicates worse outcome.
Time frame: Measured at baseline, 6 and 12 weeks
Activity of daily living, asessed with Barthel Index 20
Barthel 20 Index measures a patient's level of independence in daily activities, with scores ranging from 0 (complete dependence) to 20 (complete independence). Higher scores indicate a better outcome, reflecting greater independence.
Time frame: Measured as a retrograde baseline and at 6 and 12 weeks after intervention
Pain, assessed using the Verbal Rating Scale for pain
Hip fracture-related pain will be assessed using the Verbal Rating Scale for Pain, which ranges from 0 to 4. A score of 0 indicates no pain, while a score of 4 represents unbearable or the worst imaginable pain
Time frame: Measured at baseline and at 6 and 12 weeks after intervention
Days alive and at home up to 30 (DAH30)
The DAH30 is determined using a combination of electronic medical records (obtaining length of stay) and direct participant inquiries at the 6 week follow up
Time frame: Measured at 6 weeks after intervention.
Serious adverse event (SAE)
SAE defined following the ICH - GCP guidelines
Time frame: Will be assessed up to the 6 weeks follow up
Mortality
The time of death is determined using validated registry-based data, from which survival rates, as well as 30-day and 90-day mortality rates, are calculated.
Time frame: 90 days
A. Cost-effectiveness analysis
Explorative outcome A: Cost-effectiveness analysis will be made from a societal perspective including cost of FDI, hospital bed days, readmissions, outpatient visits and costs related to lost productivity of the patients (production loss). The analysis will be done according to the guidelines for health economic evaluation. The analysis will be based on data from the electronic patient records and data on the duration of patient's sick leave and absence from work from patient surveys. The main results from the analysis will be a comparison of the mean costs per patient in the intervention and the control group, the mean change in Quality Adjusted Life Years gained in the two groups (based on EQ5D) and the incremental cost-effectives ratio.
Time frame: 90 days post intervention
B. Physical Activity
Explorative outcome B: This outcome focuses on evaluating the effect of intravenous iron on 24-hour physical activity of patients. Physical activity will be measured using the SENS motion activity monitor. Each participant will wear the monitor for 10 days starting at the 6-week follow-up, measuring their time spent lying, sitting, standing, walking, and transitioning between these states. After 10 days, the monitor will be collected, and data will be analyzed to compare the combined amount of time spent standing and walking between the two groups. This outcome will be measured on the participants enrolled at Bispebjerg Hospital.
Time frame: SENS motion activity monitor measurements will be collected 10 days after the 6-week follow-up.
C. Hand Grip Strength
Explorative outcome C: Hand grip strength will be assessed using a dynamometer measured in kilograms with a higher score representing better hand grip strength. Measured on participants enrolled at Bispebjerg Hospital. This outcome aims to determine how intravenous iron therapy influences hand grip strength, comparing the changes between the two groups.
Time frame: Hand grip strength will be measured at baseline and again at the 6- and 12-week follow-ups.
D. Knee Extension Strength
Explorative outcome D: Knee extension strength will be measured using a dynamometer, measured in Nm/Kg with a higher score representing better Knee extension strength. Measured on participants enrolled at Bispebjerg Hospital. The goal is to examine the effect of intravenous iron therapy on knee extension strength between the two groups at these key points.
Time frame: Knee extension strength will be measured at baseline and at 6- and 12-week follow-ups.
E. Cognition assessed using, Orientation-Memory-Concentration test (OMC)
Exploratory Outcome E: Cognition will be assessed using the Orientation-Memory-Concentration (OMC) test to examine potential differences between the groups. The OMC test range from 0-28 points, with a score of 25-27 indicating no or minimal cognitive impairment, and a score of 0-7 indicating severe impairment.
Time frame: Measured at baseline, week 6 and 12 post-intervention.
F. Ferritin Levels as a Measure of Iron Status
Exploratory Outcome F: This outcome focuses on assessing the ferritin levels in both the intervention and placebo groups. Ferritin will be measured in ng/mL. The aim is to determine how intravenous iron therapy affects ferritin levels in comparison to the placebo group.
Time frame: Measured at baseline and week 6 and 12 post intervention.
G: Transferrin Saturation as a Measure of Iron Status
Explorative outcome G: Transferrin saturation, measured as a percentage, will be assessed in both the intervention and placebo groups. This outcome will evaluate how transferrin saturation is affected by intravenous iron therapy compared with placebo.
Time frame: Transferrin saturation will be measured at baseline, and at the 6- and 12-week follow-ups.
Not enrolling at this site.
Plan to share: Yes — Access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), will be provided to anyone who wishes to access the data.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Immediately following publication, no end date.
Access criteria: Any researcher, affiliated to an established institution
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.
Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 23 months is close to that.
Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000
Soren Overgaard